These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10475898)

  • 1. Decrease in endothelin-1 plasma levels during the menstrual cycle and after ethinylestradiol treatment.
    Merki-Feld GS; Keller PJ
    Ann Intern Med; 1999 Sep; 131(5):394. PubMed ID: 10475898
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of the menstrual cycle and of ethinylestradiol on nitric oxide, endothelin-1 and homocysteine plasma levels.
    Merki-Feld GS; Imthurn B; Keller PJ
    Horm Metab Res; 2000 Jul; 32(7):288-93. PubMed ID: 10965936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of plasma endothelin levels by the menstrual cycle.
    Polderman KH; Stehouwer CD; van Kamp GJ; Schalkwijk CG; Gooren LJ
    Metabolism; 2000 May; 49(5):648-50. PubMed ID: 10831177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptive estrogen and plasma lipid levels.
    Hedlin A; Kuksis A; Geher K
    Obstet Gynecol; 1978 Oct; 52(4):430-5. PubMed ID: 714324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestrogen containing oral contraceptives and antithrombin III activity.
    Rákóczi I; Nagy I; Szigetvári I; Losonczy H; Hadnagy J; Gáti I
    Acta Physiol Acad Sci Hung; 1974; 45(3-4):281-6. PubMed ID: 4471272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptives that contain ethinyl estradiol (0.035 mg) and cyproterone acetate (2 mg) inhibit leukocyte transmigration through endothelial cell monolayers.
    Hofbauer R; Frass M; Gmeiner B; Salfinger H; Salzer H; Kos T; Wagner O; Kapiotis S; Kaye AD
    Fertil Steril; 1999 Oct; 72(4):652-6. PubMed ID: 10521104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calciumantagonistic effect of natural and synthetic estrogens--investigations on a nongenomic mechanism of direct vascular action.
    Mueck AO; Seeger H; Lippert TH
    Int J Clin Pharmacol Ther; 1996 Oct; 34(10):424-6. PubMed ID: 8897079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A combiphasic oral contraceptive containing ethinylestradiol and desogestrel].
    Poulsen HK
    Ugeskr Laeger; 1995 Aug; 157(32):4473-5. PubMed ID: 7483033
    [No Abstract]   [Full Text] [Related]  

  • 9. [Safety, efficacy and control of the menstrual cycle by a monophasic oral contraceptive containing 75 mcg of gestodene and 30 mcg of ethynyl estradiol].
    Alvarado Zaldivar G; Ruiz Astorga R; Arenas Arenas M; Solis Carrera L; Rueda Cisneros D; Vázquez Arreola I
    Ginecol Obstet Mex; 1993 Oct; 61():299-303. PubMed ID: 8270225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The characteristics of triphasic estrogen-progesterone contraceptives and their theoretical indications].
    Senèze J
    Rev Fr Gynecol Obstet; 1990 May; 85(5):301-5. PubMed ID: 2374864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an oral contraceptive containing a new progestogen, desogestrel, and 30 micrograms ethinylestradiol. Report on clinical studies from Scandinavia.
    Acta Obstet Gynecol Scand Suppl; 1982; 111():1-60. PubMed ID: 6216716
    [No Abstract]   [Full Text] [Related]  

  • 12. Individual levels of plasma histidine-rich glycoprotein (HRG) during the normal menstrual cycle and in women on oral contraceptives low in oestrogen.
    Jespersen J; Kluft C
    Scand J Clin Lab Invest; 1982 Nov; 42(7):563-6. PubMed ID: 6818678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of protein S during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
    Jespersen J; Nielsen MT
    Gynecol Obstet Invest; 1989; 28(2):82-6. PubMed ID: 2529199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol.
    Bjarnadóttir RI; Tuppurainen M; Killick SR
    Am J Obstet Gynecol; 2002 Mar; 186(3):389-95. PubMed ID: 11904596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the estrogenic effect of ethinylestradiol and mestranol on the endometrium.
    Brosens IA; Pijnenborg R
    Contraception; 1976 Dec; 14(6):679-85. PubMed ID: 1017202
    [No Abstract]   [Full Text] [Related]  

  • 17. Estrogen fluctuations, oral contraceptives and borderline personality.
    DeSoto MC; Geary DC; Hoard MK; Sheldon MS; Cooper L
    Psychoneuroendocrinology; 2003 Aug; 28(6):751-66. PubMed ID: 12812862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function.
    Seeger H; Petersen G; Schulte-Wintrop E; Teichmann AT; Mueck AO
    Int J Clin Pharmacol Ther; 2002 Apr; 40(4):150-7. PubMed ID: 11996209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low dose oral contraceptives on exercise performance.
    Bryner RW; Toffle RC; Ullrich IH; Yeater RA
    Br J Sports Med; 1996 Mar; 30(1):36-40. PubMed ID: 8665116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
    Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
    Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.